Search

Your search keyword '"Pillon, Marta"' showing total 321 results
Start Over Author "Pillon, Marta" Search Limiters Available in Library Collection
321 results on '"Pillon, Marta"'

2. Late-onset and long-lasting autoimmune neutropenia: an analysis from the Italian Neutropenia Registry

Author

Fioredda, Francesca, Rotulo, Gioacchino Andrea, Farruggia, Piero, Dagliano, Francesca, Pillon, Marta, Trizzino, Angela, Notarangelo, Lucia, Luti, Laura, Lanza, Tiziana, Terranova, Paola, Lanciotti, Marina, Ceccherini, Isabella, Grossi, Alice, Porretti, Laura, Verzegnassi, Federico, Mastrodicasa, Elena, Barone, Angelica, Russo, Giovanna, Bonanomi, Sonia, Boscarol, Gianluca, Finocchi, Andrea, Veltroni, Marinella, Ramenghi, Ugo, Onofrillo, Daniela, Martire, Baldassare, Ghilardi, Roberta, Giordano, Paola, Ladogana, Saverio, Marra, Nicoletta, Zanardi, Sabrina, Beier, Fabian, Miano, Maurizio, and Dufour, Carlo

Published
2020
Full Text
View/download PDF

3. Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?

Author

Huibers, Minke Henrina Willemina, primary, Abla, Oussama, additional, Andres, Mara, additional, Balagué, Olga, additional, Beishuizen, Auke, additional, Carraro, Elisa, additional, Chiang, Alan Kwok Shing, additional, Csoka, Monika, additional, David, Bianca-Andreea, additional, de Ville de Goyet, Maelle, additional, Gilad, Gil, additional, Hori, Daiki, additional, Kotecha, Rishi Sury, additional, Kabickova, Edita, additional, Klapper, Wolfram, additional, Miakova, Natalia, additional, Minard-Colin, Véronique, additional, Nakazawa, Atsuko, additional, Pillon, Marta, additional, Rigaud, Charlotte, additional, Salaverria, Itziar, additional, Tölle, Ida, additional, Verdu-Amorós, Jaime, additional, von Mersi, Hannah, additional, Woessmann, Wilhelm, additional, Burkhardt, Birgit, additional, and Attarbaschi, A, additional

Published
2024
Full Text
View/download PDF

4. Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents

Author

Attarbaschi, Andishe, Abla, Oussama, Ronceray, Leila, Bansil, Shweta, Bomken, Simon, Burkhardt, Birgit, Ceppi, Francecso, Chiang, Alan K.S., Dave, Hema, Fedorova, Alina, Henry, Michael, Jazbec, Janez, Kabickova, Edita, Kotecha, Rishi S., Lazic, Jelena, Loeffen, Jan, Miakova, Natalia, Osumi, Tomoo, Pillon, Marta, Pourtsidis, Apostolos, Rigaud, Charlotte, Tamamyan, Gevorg, Tandon, Sneha, Uyttebroeck, Anne, Verdu-Amoros, Jamie, Woessmann, Wilhelm, Wrobel, Grazyna, and Giulino-Roth, Lisa

Published
2019
Full Text
View/download PDF

5. Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy

Author

Messina, Chiara, Zecca, Marco, Fagioli, Franca, Rovelli, Attilio, Giardino, Stefano, Merli, Pietro, Porta, Fulvio, Aricò, Maurizio, Sieni, Elena, Basso, Giuseppe, Ripaldi, Mimmo, Favre, Claudio, Pillon, Marta, Marzollo, Antonio, Rabusin, Marco, Cesaro, Simone, Algeri, Mattia, Caniglia, Maurizio, Di Bartolomeo, Paolo, Ziino, Ottavio, Saglio, Francesco, Prete, Arcangelo, and Locatelli, Franco

Published
2018
Full Text
View/download PDF

7. Current practices of follow-up programs for childhood cancer survivors in Italy

Author

Terenziani, M, Tozzi, A, Diaco, L, Biasin, E, Cattoni, A, Croci, I, Fraschini, D, Giorgiani, G, Haupt, R, Muraca, M, Pillon, M, Sironi, G, Valsecchi, M, Mastronuzzi, A, Terenziani, Monica, Tozzi, Alberto Eugenio, Diaco, Laura, Biasin, Eleonora, Cattoni, Alessandro, Croci, Ileana, Fraschini, Donatella, Giorgiani, Giovanna, Haupt, Riccardo, Muraca, Monica, Pillon, Marta, Sironi, Giovanna, Valsecchi, Maria Grazia, Mastronuzzi, Angela, Terenziani, M, Tozzi, A, Diaco, L, Biasin, E, Cattoni, A, Croci, I, Fraschini, D, Giorgiani, G, Haupt, R, Muraca, M, Pillon, M, Sironi, G, Valsecchi, M, Mastronuzzi, A, Terenziani, Monica, Tozzi, Alberto Eugenio, Diaco, Laura, Biasin, Eleonora, Cattoni, Alessandro, Croci, Ileana, Fraschini, Donatella, Giorgiani, Giovanna, Haupt, Riccardo, Muraca, Monica, Pillon, Marta, Sironi, Giovanna, Valsecchi, Maria Grazia, and Mastronuzzi, Angela

Abstract

Introduction: Quality of life in childhood cancer survivors is largely affected by survivorship care and transition from treatment to long-term follow-up (LTFU). Referring to evidence-based recommendations, we wanted to evaluate LTFU care for survivors through a survey among the Italian Association for Pediatric Hematology-Oncology (AIEOP) centers. The project aimed to evaluate the availability of services in Italy, investigate strengths and weaknesses, analyze improvements of awareness in the field, and identify the gaps that need to be addressed by different centers. Methods: Together with the family representatives, on behalf of AIEOP’s Late Effects Working Group, we developed a questionnaire on assisting childhood cancer survivors. All AIEOP centers received one questionnaire including information on local health system organizations; LTFU for childhood cancer survivors; services for adult survivors of childhood cancer; information provided to survivors/caregivers and care plan delivery. Results: Forty-eight AIEOP centers were contacted and 42 replied, with a response rate of 87.5%. The majority of respondents confirmed their interest in assisting patients with a survivorship care plan (95.2%), regardless of a clinic or dedicated staff. Discussion: This is the first overview of LTFU in Italy, which provides detailed results at national levels, prompting consideration of improvements in the last decade. Although there is a high level of interest in survivorship care, many centers lack resources to implement such programs. The identification of these challenges is useful for planning future strategies.

Published
2023

8. Autoimmune Lymphoproliferative Syndrome (ALPS) Disease and ALPS Phenotype: Are They Two Distinct Entities?

Author

Palmisani, Elena, primary, Miano, Maurizio, additional, Grossi, Alice, additional, Lanciotti, Marina, additional, Lupia, Michela, additional, Terranova, Paola, additional, Ceccherini, Isabella, additional, Montanari, Eugenia, additional, Calvillo, Michaela, additional, Pierri, Filomena, additional, Micalizzi, Concetta, additional, Maggiore, Rosario, additional, Guardo, Daniela, additional, Zanardi, Sabrina, additional, Facchini, Elena, additional, Maggio, Angela, additional, Mastrodicasa, Elena, additional, Corti, Paola, additional, Russo, Giovanna, additional, Pillon, Marta, additional, Farruggia, Piero, additional, Cesaro, Simone, additional, Barone, Angelica, additional, Tosetti, Francesca, additional, Ramenghi, Ugo, additional, Crescenzio, Nicoletta, additional, Bleesing, Jack, additional, Dufour, Carlo, additional, and Fioredda, Francesca, additional

Published
2023
Full Text
View/download PDF

9. [18F]FDG PET-MR in the Evaluation and Follow-Up of Incidental Bone Ischemic Lesions in a Mono-Center Cohort of Pediatric Patients Affected by Hodgkin’s Lymphoma

Author

Giraudo, Chiara, primary, Carraro, Elisa, additional, Cavallaro, Elena, additional, Zuliani, Monica, additional, Spampinato Gotsyak, Liliya, additional, Massano, Davide, additional, Modugno, Antonella, additional, Mussolin, Lara, additional, Biffi, Alessandra, additional, Cecchin, Diego, additional, Pillon, Marta, additional, and Zucchetta, Pietro, additional

Published
2023
Full Text
View/download PDF

11. Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry

Author

Fioredda, Francesca, primary, Zanardi, Sabrina, additional, Fragola, Martina, additional, Lanciotti, Marina, additional, Casartelli, Pietro, additional, Zuccoli, Caterina, additional, Marinoni, Maddalena, additional, Finocchi, Andrea, additional, Saettini, Francesco, additional, Bonanomi, Sonia, additional, Verzegnassi, Federico, additional, Pillon, Marta, additional, Marzollo, Antonio, additional, Barone, Angelica, additional, Mastrodicasa, Elena, additional, Onofrillo, Daniela, additional, Luti, Laura, additional, Cesaro, Simone, additional, Giacomazzi, Alice, additional, Farinasso, Loredana, additional, Licciardello, Maria, additional, Russo, Giovanna, additional, Martire, Baldassarre, additional, Menna, Giuseppe, additional, Barella, Susanna, additional, Piroddi, Antonio, additional, Cuzzubbo, Daniela, additional, Veltroni, Marinella, additional, Boscarol, Gianluca, additional, Palazzi, Giovanni, additional, Tovaglieri, Nicola, additional, Petrone, Angela, additional, Farruggia, Piero, additional, Guarina, Angela, additional, Caracchia, Giulia, additional, Notarangelo, LuciaDora, additional, and Dufour, Carlo, additional

Published
2022
Full Text
View/download PDF

13. Quantitative Plasma Proteomics to Identify Candidate Biomarkers of Relapse in Pediatric/Adolescent Hodgkin Lymphoma

Author

Repetto, Ombretta, primary, Caggiari, Laura, additional, De Zorzi, Mariangela, additional, Elia, Caterina, additional, Mussolin, Lara, additional, Buffardi, Salvatore, additional, Pillon, Marta, additional, Muggeo, Paola, additional, Casini, Tommaso, additional, Steffan, Agostino, additional, Mauz-Körholz, Christine, additional, Mascarin, Maurizio, additional, and De Re, Valli, additional

Published
2022
Full Text
View/download PDF

14. Pediatric Precursor B-Cell Lymphoblastic Malignancies: From Extramedullary to Medullary Involvement

Author

Kroeze, Emma, primary, Arias Padilla, Laura, additional, Bakker, Max, additional, Boer, Judith M., additional, Hagleitner, Melanie M., additional, Burkhardt, Birgit, additional, Mori, Takeshi, additional, Attarbaschi, Andishe, additional, Verdú-Amorós, Jaime, additional, Pillon, Marta, additional, Anderzhanova, Liliya, additional, Kabíčková, Edita, additional, Chiang, Alan K. S., additional, Kebudi, Rejin, additional, Mellgren, Karin, additional, Lazic, Jelena, additional, Jazbec, Janez, additional, Meijerink, Jules P. P., additional, Beishuizen, Auke, additional, and Loeffen, Jan L. C., additional

Published
2022
Full Text
View/download PDF

15. Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia

Author

Veltri, Giulia, primary, Lovisa, Federica, additional, Cortese, Giuliana, additional, Pillon, Marta, additional, Carraro, Elisa, additional, Cesaro, Simone, additional, Provenzi, Massimo, additional, Buffardi, Salvatore, additional, Francescato, Samuela, additional, Biffi, Alessandra, additional, Buldini, Barbara, additional, Conter, Valentino, additional, Serafin, Valentina, additional, and Mussolin, Lara, additional

Published
2022
Full Text
View/download PDF

18. Pediatric Precursor B-Cell Lymphoblastic Malignancies:From Extramedullary to Medullary Involvement

Author

Kroeze, Emma, Arias Padilla, Laura, Bakker, Max, Boer, Judith M., Hagleitner, Melanie M., Burkhardt, Birgit, Mori, Takeshi, Attarbaschi, Andishe, Verdú-Amorós, Jaime, Pillon, Marta, Anderzhanova, Liliya, Kabíčková, Edita, Chiang, Alan K.S., Kebudi, Rejin, Mellgren, Karin, Lazic, Jelena, Jazbec, Janez, Meijerink, Jules P.P., Beishuizen, Auke, Loeffen, Jan L.C., Kroeze, Emma, Arias Padilla, Laura, Bakker, Max, Boer, Judith M., Hagleitner, Melanie M., Burkhardt, Birgit, Mori, Takeshi, Attarbaschi, Andishe, Verdú-Amorós, Jaime, Pillon, Marta, Anderzhanova, Liliya, Kabíčková, Edita, Chiang, Alan K.S., Kebudi, Rejin, Mellgren, Karin, Lazic, Jelena, Jazbec, Janez, Meijerink, Jules P.P., Beishuizen, Auke, and Loeffen, Jan L.C.

Abstract

B-cell lymphoblastic lymphoma (BCP-LBL) and B-cell acute lymphoblastic leukemia (BCP-ALL) are the malignant counterparts of immature B-cells. BCP-ALL is the most common hematological malignancy in childhood, while BCP-LBL accounts for only 1% of all hematological malignancies in children. Therefore, BCP-ALL has been well studied and treatment protocols have changed over the last decades, whereas treatment for BCP-LBL has stayed roughly the same. Clinical characteristics of 364 pediatric patients with precursor B-cell malignancies were studied, consisting of BCP-LBL (n = 210) and BCP-ALL (n = 154) patients. Our results indicate that based on the clinical presentation of disease, B-cell malignancies probably represent a spectrum ranging from complete isolated medullary disease to apparent complete extramedullary disease. Hepatosplenomegaly and peripheral blood involvement are the most important discriminators, as both seen in 80% and 95% of the BCP-ALL patients and in 2% of the BCP-LBL patients, respectively. In addition, we show that the overall survival rates in this cohort differ significantly between BCP-LBL and BCP-ALL patients aged 1–18 years (p = 0.0080), and that the outcome for infants (0–1 years) with BCP-LBL is significantly decreased compared to BCP-LBL patients of all other pediatric ages (p < 0.0001).

Published
2022

19. Autoimmune neutropenia of childhood secondary to other autoimmune disorders: Data from the Italian neutropenia registry

Author

Farruggia, Piero, Puccio, Giuseppe, Fioredda, Francesca, Lanza, Tiziana, Porretti, Laura, Ramenghi, Ugo, Barone, Angelica, Bonanomi, Sonia, Finocchi, Andrea, Ghilardi, Roberta, Ladogana, Saverio, Marra, Nicoletta, Martire, Baldassare, Notarangelo, Lucia Dora, Onofrillo, Daniela, Pillon, Marta, Russo, Giovanna, Lo Valvo, Laura, Serafinelli, Jessica, Tucci, Fabio, Zunica, Fiammetta, Verzegnassi, Federico, and Dufour, Carlo

Published
2017
Full Text
View/download PDF

20. Plasma small‐extracellular vesicles enriched in miR‐122‐5p promote disease aggressiveness in pediatric anaplastic large‐cell lymphoma.

Author

Damanti, Carlotta Caterina, Ferrone, Lavinia, Gaffo, Enrico, Garbin, Anna, Tosato, Anna, Contarini, Giorgia, Gallingani, Ilaria, Angioni, Roberta, Molon, Barbara, Borile, Giulia, Carraro, Elisa, Pillon, Marta, Scarmozzino, Federico, Dei Tos, Angelo Paolo, Pizzi, Marco, Ciscato, Francesco, Rasola, Andrea, Biffi, Alessandra, Bortoluzzi, Stefania, and Lovisa, Federica

Published
2023
Full Text
View/download PDF

22. Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?

Author

Damm-Welk, Christine, primary, Lovisa, Federica, additional, Contarini, Giorgia, additional, Lüdersen, Jette, additional, Carraro, Elisa, additional, Knörr, Fabian, additional, Förster, Jan, additional, Zimmermann, Martin, additional, Sala, Alessandra, additional, Vinti, Luciana, additional, Tondo, Annalisa, additional, Pillon, Marta, additional, Woessmann, Wilhelm, additional, and Mussolin, Lara, additional

Published
2022
Full Text
View/download PDF

24. Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience

Author

Garaventa, Alberto, primary, Parodi, Stefano, additional, Guerrini, Giulia, additional, Farruggia, Piero, additional, Sala, Alessandra, additional, Pillon, Marta, additional, Buffardi, Salvatore, additional, Rossi, Francesca, additional, Bianchi, Maurizio, additional, Zecca, Marco, additional, Vinti, Luciana, additional, Facchini, Elena, additional, Casini, Tommaso, additional, Bernasconi, Sayla, additional, Amoroso, Loredana, additional, D’Amico, Salvatore, additional, Provenzi, Massimo, additional, De Santis, Raffaela, additional, Sau, Antonella, additional, Muggeo, Paola, additional, Mura, Rosa Maria, additional, Haupt, Riccardo, additional, Mascarin, Maurizio, additional, and Burnelli, Roberta, additional

Published
2022
Full Text
View/download PDF

25. [ 18 F]FDG PET-MR in the Evaluation and Follow-Up of Incidental Bone Ischemic Lesions in a Mono-Center Cohort of Pediatric Patients Affected by Hodgkin's Lymphoma.

Author

Giraudo, Chiara, Carraro, Elisa, Cavallaro, Elena, Zuliani, Monica, Spampinato Gotsyak, Liliya, Massano, Davide, Modugno, Antonella, Mussolin, Lara, Biffi, Alessandra, Cecchin, Diego, Pillon, Marta, and Zucchetta, Pietro

Subjects
HODGKIN'S disease, CHILD patients, YOUNG adults, ASYMPTOMATIC patients, BLOOD flow
Abstract

Hodgkin's lymphoma (HL) is one of the neoplasms with the best prognosis in children, adolescents and young adults, but sufferers are burdened by the possibility of developing adverse effects such as Bone Ischemic Lesions (BILs) which are lesions of the bone caused by the loss of/reduction in blood flow. The main goal of this retrospective study was to evaluate the role of [18F]FDG-PET-MR in the early detection of BILs in a single-center cohort of uniformly treated pediatric HL patients. BILs were assessed through PET-MR images as the appearance of medullary lesion surrounded by a serpiginous, tortuous border. From 2017 to 2022, 10/53 (18.9%) HL patients developed BILs which were mostly (8/10 patients) multifocal. Overall, 30 lesions were identified in the 10 asymptomatic patients, all with the above-mentioned features at MR and with very low [18F]FDG uptake. BILs were incidentally detected during HL therapy (n = 6) and follow-up (n = 4), especially in the long bones (66.7%). No factors correlated with the occurrence of BIL were identified. No patients developed complications. PET-MR is a sensitive combined-imaging technique for detecting BILs that are asymptomatic and self-limiting micro-ischemic lesions. BILs can be monitored by clinical follow-up alone both during and after therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Pearson Syndrome: A Retrospective Cohort Study from the Marrow Failure Study Group of A.I.E.O.P. (Associazione Italiana Emato-Oncologia Pediatrica)

Author

Farruggia, Piero, primary, Di Cataldo, Andrea, additional, Pinto, Rita M., additional, Palmisani, Elena, additional, Macaluso, Alessandra, additional, Valvo, Laura Lo, additional, Cantarini, Maria E., additional, Tornesello, Assunta, additional, Corti, Paola, additional, Fioredda, Francesca, additional, Varotto, Stefania, additional, Martire, Baldo, additional, Moroni, Isabella, additional, Puccio, Giuseppe, additional, Russo, Giovanna, additional, Dufour, Carlo, additional, and Pillon, Marta, additional

Published
2015
Full Text
View/download PDF

27. Primary breast lymphoma of childhood: a case report and review of literature

Author

Restivo, Giulia A., primary, Pillon, Marta, additional, Mussolin, Lara, additional, Mosa, Clara, additional, Guarina, Angela, additional, Trizzino, Angela, additional, Ialuna, Salvatore, additional, Carraro, Elisa, additional, D’Amore, Emanuele S.G., additional, Russo, Giovanna, additional, Elia, Caterina, additional, Mascarin, Maurizio, additional, Zangara, Adriana, additional, D’Angelo, Paolo, additional, and Farruggia, Piero, additional

Published
2021
Full Text
View/download PDF

28. Pediatric Anaplastic Large Cell Lymphoma with Concomitant Involvement of Spine and Central Nervous System: A Case Report and Review of Literature

Author

Restivo, Giulia A., primary, Mussolin, Lara, additional, D’Angelo, Paolo, additional, Trizzino, Angela, additional, Ialuna, Salvatore, additional, Sabattini, Elena, additional, Gallo, Cristina, additional, Toscano, Angelo, additional, Carraro, Elisa, additional, Pillon, Marta, additional, and Farruggia, Piero, additional

Published
2021
Full Text
View/download PDF

29. Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience

Author

Lovisa, Federica, primary, Gallingani, Ilaria, additional, Varotto, Elena, additional, Pasin, Cristiano, additional, Carraro, Elisa, additional, Michielotto, Barbara, additional, Garbin, Anna, additional, Damanti, Carlotta Caterina, additional, Pizzi, Marco, additional, d’Amore, Emanuele S. G., additional, Piglione, Matilde, additional, Muggeo, Paola, additional, Buffardi, Salvatore, additional, Vinti, Luciana, additional, Folsi, Veronica Maria, additional, Onofrillo, Daniela, additional, Biffi, Alessandra, additional, Buldini, Barbara, additional, Pillon, Marta, additional, and Mussolin, Lara, additional

Published
2021
Full Text
View/download PDF

31. Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients

Author

Veltri, Giulia, primary, Silvestri, Chiara, additional, Gallingani, Ilaria, additional, Sandei, Max, additional, Vencato, Sara, additional, Lovisa, Federica, additional, Cortese, Giuliana, additional, Pillon, Marta, additional, Carraro, Elisa, additional, Bresolin, Silvia, additional, Biffi, Alessandra, additional, Basso, Giuseppe, additional, Accordi, Benedetta, additional, Mussolin, Lara, additional, and Serafin, Valentina, additional

Published
2021
Full Text
View/download PDF

32. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations

Author

Burkhardt, B, Taj, M, Garnier, N, Minard-Colin, V, Hazar, V, Mellgren, K, Osumi, T, Fedorova, A, Myakova, N, Verdu-Amoros, J, Andres, M, Kabickova, E, Attarbaschi, A, Chiang, A, Bubanska, E, Donska, S, Hjalgrim, L, Wachowiak, J, Pieczonka, A, Uyttebroeck, A, Lazic, J, Loeffen, J, Buechner, J, Niggli, F, Csoka, M, Krivan, G, Palma, J, Burke, G, Beishuizen, A, Koeppen, K, Mueller, S, Herbrueggen, H, Woessmann, W, Zimmermann, M, Balduzzi, A, Pillon, M, Burkhardt, Birgit, Taj, Mary, Garnier, Nathalie, Minard-Colin, Veronique, Hazar, Volkan, Mellgren, Karin, Osumi, Tomoo, Fedorova, Alina, Myakova, Natalia, Verdu-Amoros, Jaime, Andres, Mara, Kabickova, Edita, Attarbaschi, Andishe, Chiang, Alan Kwok Shing, Bubanska, Eva, Donska, Svetlana, Hjalgrim, Lisa Lyngsie, Wachowiak, Jacek, Pieczonka, Anna, Uyttebroeck, Anne, Lazic, Jelena, Loeffen, Jan, Buechner, Jochen, Niggli, Felix, Csoka, Monika, Krivan, Gergely, Palma, Julia, Burke, G A Amos, Beishuizen, Auke, Koeppen, Kristin, Mueller, Stephanie, Herbrueggen, Heidi, Woessmann, Wilhelm, Zimmermann, Martin, Balduzzi, Adriana, Pillon, Marta, Burkhardt, B, Taj, M, Garnier, N, Minard-Colin, V, Hazar, V, Mellgren, K, Osumi, T, Fedorova, A, Myakova, N, Verdu-Amoros, J, Andres, M, Kabickova, E, Attarbaschi, A, Chiang, A, Bubanska, E, Donska, S, Hjalgrim, L, Wachowiak, J, Pieczonka, A, Uyttebroeck, A, Lazic, J, Loeffen, J, Buechner, J, Niggli, F, Csoka, M, Krivan, G, Palma, J, Burke, G, Beishuizen, A, Koeppen, K, Mueller, S, Herbrueggen, H, Woessmann, W, Zimmermann, M, Balduzzi, A, Pillon, M, Burkhardt, Birgit, Taj, Mary, Garnier, Nathalie, Minard-Colin, Veronique, Hazar, Volkan, Mellgren, Karin, Osumi, Tomoo, Fedorova, Alina, Myakova, Natalia, Verdu-Amoros, Jaime, Andres, Mara, Kabickova, Edita, Attarbaschi, Andishe, Chiang, Alan Kwok Shing, Bubanska, Eva, Donska, Svetlana, Hjalgrim, Lisa Lyngsie, Wachowiak, Jacek, Pieczonka, Anna, Uyttebroeck, Anne, Lazic, Jelena, Loeffen, Jan, Buechner, Jochen, Niggli, Felix, Csoka, Monika, Krivan, Gergely, Palma, Julia, Burke, G A Amos, Beishuizen, Auke, Koeppen, Kristin, Mueller, Stephanie, Herbrueggen, Heidi, Woessmann, Wilhelm, Zimmermann, Martin, Balduzzi, Adriana, and Pillon, Marta

Abstract

Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.

Published
2021

33. ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Author

Elitzur, Sarah, Shiloh, Ruth, Loeffen, Jan, Pastorczak, Agata, Takagi, Masatoshi, Bomken, Simon, Baruchel, Andre, Ducassou, Stephane, Mahlaoui, Nizar, Strullu, Marion, Lehrnbecher, Thomas, Schmiegelow, Kjeld, Abla, Oussama, Anderzhanova, Liliia, Arad-Cohen, Nira, Astigarraga, Itziar, Ben-Harosh, Miriam, Ceppi, Francesco, Bodmer, Nicole, Brozou, Triantafyllia, Dalla-Pozza, Luciano, Escherich, Gabriele, Farah, Roula, Gibson, Amber, Hasle, Henrik, Hoveyan, Julieta, Jacoby, Elad, Jazbec, Janez, Kolenova, Alexandra, Lazic, Jelena, Lo Nigro, Luca, Miller, Lane, Papadakis, Vassilios, Pecheux, Lucie, Pillon, Marta, Sarouk, Ifat, Stary, Jan, Stiakaki, Eftichia, Tasian, Sarah K., Tran, Thai Hoa, Ussowicz, Marek, Verdu-Amoros, Jose Jaime, Wakulinska, Anna, Zawitkowska, Joanna, Stoppa-Lyonnet, Dominique, Taylor, Malcolm, Shiloh, Yosef, Izraeli, Shai, Nirel, Ronit, Minard-Colin, Veronique, Attarbaschi, Andishe, and Borkhardt, Arndt

Published
2023
Full Text
View/download PDF

35. Low miR-214-5p Expression Correlates With Aggressive Subtypes of Pediatric ALCL With Non-Common Histology

Author

Di Battista, Piero, primary, Lovisa, Federica, additional, Gaffo, Enrico, additional, Gallingani, Ilaria, additional, Damanti, Carlotta C., additional, Garbin, Anna, additional, Ferrone, Lavinia, additional, Carraro, Elisa, additional, Pillon, Marta, additional, Lo Nigro, Luca, additional, Mura, Rossella, additional, Pizzi, Marco, additional, Guzzardo, Vincenza, additional, Dei Tos, Angelo Paolo, additional, Biffi, Alessandra, additional, Bortoluzzi, Stefania, additional, and Mussolin, Lara, additional

Published
2021
Full Text
View/download PDF

36. Proteomic Exploration of Plasma Exosomes and Other Small Extracellular Vesicles in Pediatric Hodgkin Lymphoma: A Potential Source of Biomarkers for Relapse Occurrence

Author

Repetto, Ombretta, primary, Lovisa, Federica, additional, Elia, Caterina, additional, Enderle, Daniel, additional, Romanato, Filippo, additional, Buffardi, Salvatore, additional, Sala, Alessandra, additional, Pillon, Marta, additional, Steffan, Agostino, additional, Burnelli, Roberta, additional, Mussolin, Lara, additional, Mascarin, Maurizio, additional, and De Re, Valli, additional

Published
2021
Full Text
View/download PDF

37. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations

Author

Burkhardt, Birgit, primary, Taj, Mary, additional, Garnier, Nathalie, additional, Minard-Colin, Veronique, additional, Hazar, Volkan, additional, Mellgren, Karin, additional, Osumi, Tomoo, additional, Fedorova, Alina, additional, Myakova, Natalia, additional, Verdu-Amoros, Jaime, additional, Andres, Mara, additional, Kabickova, Edita, additional, Attarbaschi, Andishe, additional, Chiang, Alan Kwok Shing, additional, Bubanska, Eva, additional, Donska, Svetlana, additional, Hjalgrim, Lisa Lyngsie, additional, Wachowiak, Jacek, additional, Pieczonka, Anna, additional, Uyttebroeck, Anne, additional, Lazic, Jelena, additional, Loeffen, Jan, additional, Buechner, Jochen, additional, Niggli, Felix, additional, Csoka, Monika, additional, Krivan, Gergely, additional, Palma, Julia, additional, Burke, G. A. Amos, additional, Beishuizen, Auke, additional, Koeppen, Kristin, additional, Mueller, Stephanie, additional, Herbrueggen, Heidi, additional, Woessmann, Wilhelm, additional, Zimmermann, Martin, additional, Balduzzi, Adriana, additional, and Pillon, Marta, additional

Published
2021
Full Text
View/download PDF

39. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children

Author

Minard-Colin, Véronique, Aupérin, Anne, Pillon, Marta, Burke, G A Amos, Barkauskas, Donald A, Wheatley, Keith, Delgado, Rafael F, Alexander, Sarah, Uyttebroeck, Anne, Bollard, Catherine M, Zsiros, József, Csoka, Monika, Kazanowska, Bernarda, Chiang, Alan K, Miles, Rodney R, Wotherspoon, Andrew, Adamson, Peter C, Vassal, Gilles, Patte, Catherine, Gross, Thomas G, European Intergroup for Childhood Non-Hodgkin Lymphoma, Children’s Oncology Group, Brichard, Bénédicte, Clinical sciences, Growth and Development, Pediatrics, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, and UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique

Subjects
Oncology, Male, Pediatrics, medicine.medical_treatment, Lymphoma, B-Cell/drug therapy, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Rituximab/administration & dosage, Antineoplastic Agents, Immunological, 0302 clinical medicine, Neutropenia/chemically induced, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Child, Infusions, Intravenous, Medicine(all), General Medicine, Progression-Free Survival, Mature B-Cell Non-Hodgkin's Lymphoma, Rituximab, Female, Lymph, medicine.drug, medicine.medical_specialty, Lymphoma, B-Cell, Neutropenia, Adolescent, Child, preschool, Infections/etiology, MEDLINE, Infections, Article, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Internal medicine, medicine, Humans, Progression-free survival, Chemotherapy, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cancer, medicine.disease, Lymphoma, Clinical trial, business, Follow-Up Studies
Abstract

BACKGROUND: Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited. METHODS: We conducted an open-label, international, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed. RESULTS: Analyses were based on 328 patients who underwent randomization (164 patients per group); 85.7% of the patients had Burkitt's lymphoma. The median follow-up was 39.9 months. Events were observed in 10 patients in the rituximab-chemotherapy group and in 28 in the chemotherapy group. Event-free survival at 3 years was 93.9% (95% confidence interval [CI], 89.1 to 96.7) in the rituximab-chemotherapy group and 82.3% (95% CI, 75.7 to 87.5) in the chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer, 0.32; 95% CI, 0.15 to 0.66; one-sided P = 0.00096, which reached the significance level required for this analysis). Eight patients in the rituximab-chemotherapy group died (4 deaths were disease-related, 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17 deaths were disease-related, and 3 were treatment-related) (hazard ratio, 0.36; 95% CI, 0.16 to 0.82). The incidence of acute adverse events of grade 4 or higher after prephase treatment was 33.3% in the rituximab-chemotherapy group and 24.2% in the chemotherapy group (P = 0.07); events were related mainly to febrile neutropenia and infection. Approximately twice as many patients in the rituximab-chemotherapy group as in the chemotherapy group had a low IgG level 1 year after trial inclusion. CONCLUSIONS: Rituximab added to standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin's lymphoma and was associated with a higher incidence of hypogammaglobulinemia and, potentially, more episodes of infection. (Funded by the Clinical Research Hospital Program of the French Ministry of Health and others; ClinicalTrials.gov number, NCT01516580.).

Published
2020

40. Atypical Autoimmune Neutropenia: Data from The Italian Neutropenia Registry

Author

Fioredda, Francesca, Farruggia, Piero, Rotulo, Andrea, Pillon, Marta, Trizzino, Angela, Notarangelo, Lucia Dora, Luti, Laura, Lanza, Tiziana, Lanciotti, Marina, Isabella, Ceccherini, Alice, Grossi, Porretti, Laura, Matrodicasa, Elena, Barone, Angelica, Russo, Giovanna, Bonanomi, Sonia, Boscarol, Gianluca, Finocchi, Andrea, Veltroni, Marinella, Ramenghi, Ugo, Onofrillo, Daniela, Verzegnassi, Federico, Martire, Baldo, Ghilardi, Roberta, Lassandro, Giuseppe, La Dogana, Saverio, Marra, Nicoletta, PAOLA TERRANOVA, Zanardi, Sabrina, Dufour, Carlo, and Miano, Maurizio

Published
2020

41. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children

Author

UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Minard-Colin, Véronique, Aupérin, Anne, Pillon, Marta, Burke, G A Amos, Barkauskas, Donald A, Wheatley, Keith, Delgado, Rafael F, Alexander, Sarah, Uyttebroeck, Anne, Bollard, Catherine M, Zsiros, József, Csoka, Monika, Kazanowska, Bernarda, Chiang, Alan K, Miles, Rodney R, Wotherspoon, Andrew, Adamson, Peter C, Vassal, Gilles, Patte, Catherine, Gross, Thomas G, European Intergroup for Childhood Non-Hodgkin Lymphoma, Children’s Oncology Group, Brichard, Bénédicte, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Minard-Colin, Véronique, Aupérin, Anne, Pillon, Marta, Burke, G A Amos, Barkauskas, Donald A, Wheatley, Keith, Delgado, Rafael F, Alexander, Sarah, Uyttebroeck, Anne, Bollard, Catherine M, Zsiros, József, Csoka, Monika, Kazanowska, Bernarda, Chiang, Alan K, Miles, Rodney R, Wotherspoon, Andrew, Adamson, Peter C, Vassal, Gilles, Patte, Catherine, Gross, Thomas G, European Intergroup for Childhood Non-Hodgkin Lymphoma, Children’s Oncology Group, and Brichard, Bénédicte

Abstract

BACKGROUND: Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited. METHODS: We conducted an open-label, international, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed. RESULTS: Analyses were based on 328 patients who underwent randomization (164 patients per group); 85.7% of the patients had Burkitt's lymphoma. The median follow-up was 39.9 months. Events were observed in 10 patients in the rituximab-chemotherapy group and in 28 in the chemotherapy group. Event-free survival at 3 years was 93.9% (95% confidence interval [CI], 89.1 to 96.7) in the rituximab-chemotherapy group and 82.3% (95% CI, 75.7 to 87.5) in the chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer, 0.32; 95% CI, 0.15 to 0.66; one-sided P = 0.00096, which reached the significance level required for this analysis). Eight patients in the rituximab-chemotherapy group died (4 deaths were disease-related, 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17 deaths were disease-related, and 3 were treatment-related) (hazard ratio, 0.36; 95% CI, 0.16 to 0.82). The incidence of acute adverse events of grade 4 or higher after prephase treatment was 33.3% in the rituximab-chemotherapy group and 24.2% in the chemotherapy group (P = 0.07); events were related mainly to febrile neutropenia and infection. Approximately twice

Published
2020

42. Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers?

Author

Lovisa, Federica, primary, Garbin, Anna, additional, Crotti, Sara, additional, Di Battista, Piero, additional, Gallingani, Ilaria, additional, Damanti, Carlotta Caterina, additional, Tosato, Anna, additional, Carraro, Elisa, additional, Pillon, Marta, additional, Mafakheri, Erfan, additional, Romanato, Filippo, additional, Gaffo, Enrico, additional, Biffi, Alessandra, additional, Bortoluzzi, Stefania, additional, Agostini, Marco, additional, and Mussolin, Lara, additional

Published
2021
Full Text
View/download PDF

43. MiR-26a-5p as a Reference to Normalize MicroRNA qRT-PCR Levels in Plasma Exosomes of Pediatric Hematological Malignancies

Author

Damanti, Carlotta C., primary, Gaffo, Enrico, additional, Lovisa, Federica, additional, Garbin, Anna, additional, Di Battista, Piero, additional, Gallingani, Ilaria, additional, Tosato, Anna, additional, Pillon, Marta, additional, Carraro, Elisa, additional, Mascarin, Maurizio, additional, Elia, Caterina, additional, Biffi, Alessandra, additional, Bortoluzzi, Stefania, additional, and Mussolin, Lara, additional

Published
2021
Full Text
View/download PDF

45. Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica)

Author

Fioredda, Francesca, Calvillo, Michaela, Bonanomi, Sonia, Coliva, Tiziana, Tucci, Fabio, Farruggia, Piero, Pillon, Marta, Martire, Baldassarre, Ghilardi, Roberta, Ramenghi, Ugo, Renga, Daniela, Menna, Giuseppe, Pusiol, Anna, Barone, Angelica, Gambineri, Eleonora, Palazzi, Giovanni, Casazza, Gabriella, Lanciotti, Marina, and Dufour, Carlo

Published
2012
Full Text
View/download PDF

47. Multidisciplinary expertise in the diagnosis of cecal lymphoma

Author

Brooks, Giulia, primary, Andreetta, Marina, additional, Fascetti Leon, Francesco, additional, Mognato, Guendalina, additional, Virgone, Calogero, additional, Zuliani, Monica, additional, Fantin, Alberto, additional, Pillon, Marta, additional, Santoro, Luisa, additional, Gamba, Piergiorgio, additional, and Dall’Igna, Patrizia, additional

Published
2020
Full Text
View/download PDF

49. Comparison of Hodgkin’s Lymphoma in Children and Adolescents. A Twenty Year Experience with MH’96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols

Author

Burnelli, Roberta, primary, Fiumana, Giulia, additional, Rondelli, Roberto, additional, Pillon, Marta, additional, Sala, Alessandra, additional, Garaventa, Alberto, additional, D’Amore, Emanuele S.G., additional, Sabattini, Elena, additional, Buffardi, Salvatore, additional, Bianchi, Maurizio, additional, Vinti, Luciana, additional, Zecca, Marco, additional, Muggeo, Paola, additional, Provenzi, Massimo, additional, Farruggia, Piero, additional, Rossi, Francesca, additional, D’Amico, Salvatore, additional, Facchini, Elena, additional, Bernasconi, Sayla, additional, De Santis, Raffaela, additional, Casini, Tommaso, additional, Porta, Fulvio, additional, D’Alba, Irene, additional, Mura, Rosamaria, additional, Verzegnassi, Federico, additional, Sau, Antonella, additional, Cesaro, Simone, additional, Perruccio, Katia, additional, Cellini, Monica, additional, Bertolini, Patrizia, additional, Sperlì, Domenico, additional, Pericoli, Roberta, additional, Galimberti, Daniela, additional, Civino, Adele, additional, and Mascarin, Maurizio, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results